BCR-ABL, identified in 1985 as the cause of malignant transformation in Ph+ CML,4 served as the target for design of tyrosine kinase inhibitors (TKIs). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.